[{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts","type":"changed","fields":[{"field":"tldr","before":"\"China's national oncology guidelines, notable for grading recommendations by both evidence and affordability, and for covering Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in China (nasopharynge...","after":"\"CSCO guidelines are China's national oncology guidelines, notable for grading recommendations by both evidence and affordability, and for covering Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in..."}]},{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","route":"/collections/csco-guidelines/","commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"url"},{"field":"holds"},{"field":"maintainer"},{"field":"license"},{"field":"tldr"},{"field":"summary"},{"field":"related"},{"field":"institutions"},{"field":"drugs"},{"field":"links"},{"field":"tags"}]}]